Sign in Subscribe
Pharmaceutical industry

NeuroVive Pharmaceutical and to-BBB Receive €1 Million Grant for Stroke Treatment Development

Strategic Insights

— 1 min read

NeuroVive Pharmaceutical AB and to-BBB, a Dutch brain drug delivery company, have been awarded a €1 million grant through the Eureka Eurostars program for the joint development of therapies for stroke and other acute neurological conditions. This grant will support their preclinical development program on a potential new treatment for stroke patients, combining NeuroVive's cyclosporin A with to-BBB's G-Technology to enhance delivery of the drug across the blood-brain barrier.

Key Takeaways:

  • The Eureka Eurostars program has awarded NeuroVive Pharmaceutical and to-BBB a grant of €1 million to support the joint development of therapies for stroke and other acute neurological conditions.
  • NeuroVive's cyclosporin A will be combined with to-BBB's G-Technology to enhance delivery of the drug across the blood-brain barrier.
  • The two companies have been working together since October 2010, and the Eurostars grant solidifies and accelerates their partnership.
  • Pieter Gaillard, CSO of to-BBB, notes that the blood-brain barrier limits drug penetration in stroke patients when they need it most, and to-BBB's proprietary G-Technology holds promise to enhance brain delivery of cyclosporin-based pharmaceuticals.
  • The strategic collaboration between NeuroVive and to-BBB aims to generate therapies for the large stroke market and other acute neurological conditions.
  • The Eurostars program is designed to stimulate SMEs to lead international collaborative research and innovation projects by easing access to support and funding.
  • NeuroVive Pharmaceutical AB is a Swedish drug development company specializing in the treatment of acute brain injury, reperfusion injury in myocardial infarction, and other acute injuries where mitochondrial energy production is critical for clinical outcome.
  • to-BBB is a clinical stage biotechnology company focusing on enhanced drug delivery across the blood-brain barrier, developing treatments for brain disorders by combining existing drugs with the G-Technology.

Statistics:

  • The Eureka Eurostars program has awarded NeuroVive Pharmaceutical and to-BBB a grant of €1 million to support their joint development program.
  • The grant is approximately €500,000 each for the two companies.
  • The two companies have been working together since October 2010.
  • The Eurostars program has awarded approximately €500,000 to each of the selected 348 initiatives.
  • The partnership aims to generate therapies for the large stroke market.

Sources:

  • NeuroVive Pharmaceutical AB via Thomson Reuters ONE
  • Marketwire, Inc.
  • Eureka Eurostars program

Read more